At Saberg Clinical Research, we are commited to providing cutting-edge medical research.
At Saberg Clinical Research, we are commited to providing cutting-edge medical research.
About us
The highly skilled and experienced team at Saberg Clinical Research includes:
-
MDs / MD, PhDs and scientists with relevant backgrounds, with a proven track record in drug development, medical monitoring, pharmacovigilance, and medical writing.
-
Internationally recognized consultants and scientific advisors.
-
An extensive network of investigators and research sites covering but not limited to Europe, the United States, and Canada. Our network of investigators includes specialists with an excellent record of scientific integrity and high patient enrollment rates.
​
​
Sandrin Bergheanu
CEO
Sandrin Bergheanu, MD, PhD is a physician - clinical pharmacologist with more than 10 years of experience in drug development, including designing, executing, and managing clinical trials.
Sandrin graduated from the Carol Davila Medical School in Bucharest, Romania. He then worked at the University Hospital of Geneva (HUG), Switzerland before moving to the Cardiology Department at Leiden University Medical Center (LUMC) in Leiden, the Netherlands. While at LUMC, he obtained his PhD in Cardiovascular Research through a combined program at the Department of Cardiology and the Department of Clinical Epidemiology. Sandrin was trained as a clinical pharmacologist at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands and LUMC. Sandrin has also received extensive training in clinical epidemiology, clinical study design, and biostatistics. He has participated in the design, set-up, and execution of clinical studies for the pharmaceutical industry, medical device companies, and academic consortia.
Prior to founding Saberg Clinical Research, Sandrin was the Medical Director at Sticares (a Netherlands-based CRO that specializes in cardiovascular research) and clinical research physician/medical advisor at Eli Lilly and Company. At Sticares, Sandrin coordinated and supervised all medical activities in phase I, phase II, and large phase III trials.
Sandrin speaks English, Dutch, French, Italian and Romanian.
​